# Optimization of donor structure enhances the generation of cloned goats with high expression of human butyrylcholinesterase by CRISPR/Cas9

**Authors:** Yunpeng Wu, Jianhua Zheng, Jingqing Chen, Tianqi Sun, Tianqi Luan, Yan Li, Yunzhi Fa, Yefeng Qiu, Rui Zhang

PMC · DOI: 10.3389/fbioe.2025.1633553 · Frontiers in Bioengineering and Biotechnology · 2025-11-10

## TL;DR

Scientists improved CRISPR editing in goats to produce high levels of a human enzyme that can protect against nerve agents.

## Contribution

A novel donor structure optimization strategy significantly enhances HDR efficiency in large animal genome editing.

## Key findings

- Reverse-oriented donor structures significantly improved HDR efficiency compared to forward designs.
- Cloned goats expressed high levels of human butyrylcholinesterase in their skin.
- Edited cells showed increased resistance to organophosphorus pesticides.

## Abstract

Human butyrylcholinesterase (hBChE) is a promising bioscavenger against organophosphorus (OP) nerve agents and pesticides. However, low homology-directed repair (HDR) efficiency in CRISPR/Cas9-mediated genome editing limits precise transgene integration in large animals.

To improve HDR, we optimized donor structure for targeted integration of hBChE into the goat FGF5 locus using CRISPR/Cas9. Correctly edited goat fibroblast clones were identified by PCR and sequencing. A homozygous clone with reverse-oriented integration was used as a donor for somatic cell nuclear transfer (SCNT), followed by embryo transfer. Offspring were analyzed for genomic integration and transgene expression.

Reverse-oriented donors significantly enhanced HDR efficiency compared to forward designs, with validation at the pig RAG1 locus. Edited cells stably expressed recombinant hBChE (rhBChE) and showed increased resistance to OP pesticides. SCNT produced a cloned goat expressing high rhBChE levels in the skin.

Optimizing donor structure improves precise genome editing efficiency and enables robust generation of transgenic goats. This strategy advances CRISPR/Cas9-based bioreactor development for scalable production of therapeutic proteins.

## Linked entities

- **Genes:** FGF5 (fibroblast growth factor 5) [NCBI Gene 2250], RAG1 (recombination activating 1) [NCBI Gene 5896]
- **Chemicals:** OP (PubChem CID 44247677)

## Full-text entities

- **Genes:** butyrylcholinesterase [NCBI Gene 102187168], FGF5 [NCBI Gene 102171226], RAG1 [NCBI Gene 102173108]
- **Chemicals:** OP pesticides (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823], Capra hircus (domestic goat, species) [taxon 9925]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12641187/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12641187/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12641187/full.md

---
Source: https://tomesphere.com/paper/PMC12641187